Investigating the role of STARD3 in colorectal cancer
The Theranostic Value of STARD3 in Colorectal Cancer: The STAR Study: a Monocentric Observational Study
This study is testing if a protein called STARD3 is linked to colorectal cancer and if it can help doctors understand how the cancer grows and responds to treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centro di Riferimento Oncologico - Aviano Academic / other |
| Locations | 1 site (Aviano, Pordenone) |
| Trial ID | NCT06136949 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on colorectal cancer (CRC) patients to verify the overexpression of STARD3 in tumor tissues, both in early and advanced stages. It aims to identify the pathways involved in tumorigenesis and cancer progression related to STARD3, while also exploring its potential as a dynamic biomarker for treatment response. The study utilizes patient-derived organoids to assess drug sensitivity and treatment efficacy in a controlled ex-vivo environment. By analyzing these organoids, researchers hope to gain insights into the therapeutic implications of STARD3 in CRC.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a histologically confirmed diagnosis of colorectal cancer, regardless of the stage.
Not a fit: Patients who are pregnant, breastfeeding, or have a history of other malignancies within the past five years may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and therapeutic strategies for colorectal cancer patients.
How similar studies have performed: While the specific approach of using STARD3 as a theranostic target is novel, similar studies utilizing organoids for drug sensitivity testing have shown promise in cancer research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically confirmed diagnosis of colorectal cancer, independently from diagnosis stage. * Age ≥18 years. * Signed informed consent form. * Availability of tissue and blood samples stored at the Institutional Biobank for research purposes. Exclusion Criteria: * Patients for which the tumour biobanking process could compromise the diagnostic assessments. * Pregnancy or breast-feeding. * History of concomitant or previous malignancy in the previous 5 years, except for adequately treated cutaneous squamous cell carcinoma or surgically removed in situ cervical carcinoma.
Where this trial is running
Aviano, Pordenone
- Centro di Riferimento Oncologico (CRO) di Aviano - IRCCS — Aviano, Pordenone, Italy (Recruiting)
Study contacts
- Principal investigator: Vincenzo Canzonieri, MD,PhD — Centro di Riferimento Oncologico di Aviano (CRO) - IRCCS
- Study coordinator: Vincenzo Canzonieri, MD, PhD
- Email: vcanzonieri@cro.it
- Phone: 0434 659 618
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.